Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

NEJM Data Underscore DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 7th 2021

Courtney Marabella

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

Kyle Doherty

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer

September 7th 2021

Caroline Seymour

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Management of Toxicities Is Crucial to Immunotherapy Combination Use in HCC

September 7th 2021

Ryan Scott

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Cancer-Specific Mortality Shows Variable Risk Throughout Neuroendocrine Tumors

September 7th 2021

Caroline Seymour

The risk of cancer-specific death was significantly higher than the risk of noncancer death in patients with neuroendocrine tumors, despite the reported heterogeneity by primary tumor site.

CLL: Final Thoughts

September 7th 2021

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

September 7th 2021

Jackie Collins

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Emerging Agents for R/R CLL

September 7th 2021

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Challenges in Myelofibrosis Treatment

September 7th 2021

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center

Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.

Triple Therapy Approaches for mCSPC

September 7th 2021

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

Case 3: Indolent Systemic Mastocytosis

September 7th 2021

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.

Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

Mark A. Socinski, MD

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Avapritinib: Approval and Clinical Practice Implications

September 7th 2021

Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.

Pharmacoeconomic Considerations for Immunotherapy

September 7th 2021

Mark A. Socinski, MD

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

ADT Monotherapy in mCSPC

September 7th 2021

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

See All News